Exploring the chemical space of 1,2,3-triazolyl triclosan analogs for discovery of new antileishmanial chemotherapeutic agents
Triclosan and isoniazid are known antitubercular compounds that have proven to be also active against Leishmania parasites. On these grounds, a collection of 37 diverse 1,2,3-triazoles based on the antitubercular molecules triclosan and 5-octyl-2-phenoxyphenol (8PP) were designed in search of novel...
Saved in:
Published in: | RSC medicinal chemistry Vol. 12; no. 1; pp. 12 - 128 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Royal Society of Chemistry
01-01-2021
RSC |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Triclosan and isoniazid are known antitubercular compounds that have proven to be also active against
Leishmania
parasites. On these grounds, a collection of 37 diverse 1,2,3-triazoles based on the antitubercular molecules triclosan and 5-octyl-2-phenoxyphenol (8PP) were designed in search of novel structures with leishmanicidal activity and prepared using different alkynes and azides. The 37 compounds were assayed against
Leishmania donovani
, the etiological agent of leishmaniasis, yielding some analogs with activity at micromolar concentrations and against
M. tuberculosis
H37Rv resulting in scarce active compounds with an MIC of 20 μM. To study the mechanism of action of these catechols, we analyzed the inhibition activity of the library on the
M. tuberculosis
enoyl-ACP reductase (ENR) InhA, obtaining poor inhibition of the enzyme. The cytotoxicity against Vero cells was also tested, resulting in none of the compounds being cytotoxic at concentrations of up to 20 μM. Derivative
5f
could be considered a valuable starting point for future antileishmanial drug development. The validation of a putative leishmanial InhA orthologue as a therapeutic target needs to be further investigated.
A collection of 37 triazolyl-triclosan derivatives were prepared as possible antileishmanial drugs. The InhA ortholog in
Leishmania donovani
was proposed as a putative druggable target. |
---|---|
Bibliography: | 10.1039/d0md00291g Electronic supplementary information (ESI) available. See DOI ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work. Present address: Department of Infectious Diseases, Division of Drug Discovery, Southern Research, Birmingham, AL 35205, USA. Present address: Department of Microbiology, Immunology & Pathology, Colorado State University, 1682 Campus Delivery, Fort Collins, CO 80523, USA. |
ISSN: | 2632-8682 2632-8682 |
DOI: | 10.1039/d0md00291g |